Shares of Keryx Biopharmaceuticals (NASDAQ:KERX), a drug developer with a focus on renal disease, had an awful month: Shares were down nearly 40% in September.
What caused the huge downward move? See the presentation below for details.
Why Keryx Biopharmaceuticals Was Obliterated in September
Shares fell a huge 39% in September. Was there any news to justify the sell-off?
Brian Feroldi
Oct 25, 2015 at 6:01PM
Author
Brian Feroldi
Brian Feroldi has been covering the healthcare and technology industries for the Motley Fool since 2015. Brian's investing goal is to find the highest quality companies that he can find, buy them, and then to sit back and let compounding work its magic. See all of his articles here and make sure you follow him on Twitter. Follow @brianferoldi
Article Info
- Oct 25, 2015 at 6:01PM
- Health Care
